Redcare Pharmacy stock (NL0012044747): Online pharmacy leader expands in Germany

Redcare Pharmacy, Europe's leading online pharmacy, reported strong Q1 growth with revenue up 25% year-over-year, driven by its Shop Apotheke platform. The stock trades on the Frankfurt Stock Exchange.

Redcare Pharmacy SE, operating as Shop Apotheke, continues to capitalize on the shift to digital health services in Europe. The company released its first-quarter 2026 results on May 8, 2026, showing revenue of €248 million, a 25% increase from €198 million in Q1 2025, according to Redcare Pharmacy IR as of 05/08/2026. This performance underscores its dominant position in the German online pharmacy market.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Redcare Pharmacy SE
• Sector/industry: Healthcare / Online Pharmacy
• Headquarters/country: Netherlands / Germany-focused
• Core markets: Germany, Netherlands, Austria, Belgium
• Key revenue drivers: Online prescription and OTC drug sales
• Home exchange/listing venue: Frankfurt Stock Exchange (FRA: RDC)
• Trading currency: EUR

Redcare Pharmacy: core business model

Redcare Pharmacy SE operates Europe's largest online pharmacy platform under the Shop Apotheke brand. Founded in 1998 and headquartered in Sevenum, Netherlands, it delivers prescription and over-the-counter medications directly to consumers across multiple countries. The model combines e-commerce efficiency with regulatory-compliant pharmacy services, processing over 10 million orders annually as reported in its 2025 annual report published March 2026, per company IR as of 03/2026.

The business benefits from high fixed costs in logistics and IT, enabling scalable growth as order volumes rise. Key to its success is proprietary software for inventory management and personalized recommendations, which drives repeat customer rates above 80%.

Main revenue and product drivers for Redcare Pharmacy

Revenue primarily stems from pharmaceutical sales, with 85% from prescription drugs in Q1 2026. Growth is fueled by expanding active customers, which reached 3.2 million, up 18% year-over-year, according to the Q1 earnings release. Non-pharma categories like beauty and wellness products contribute 15%, diversifying income streams.

In Germany, its largest market generating 70% of sales, Shop Apotheke holds a leading position with market share exceeding 20%, per Statista data published April 2026 on Statista as of 04/2026. US investors note exposure via Europe's aging population and rising telehealth adoption, mirroring US trends.

Industry trends and competitive position

The European online pharmacy sector is projected to grow at 15% CAGR through 2030, driven by convenience and post-pandemic digital habits, according to a S&P Global report from February 2026. Redcare Pharmacy outperforms peers with superior margins, achieving an adjusted EBITDA of €12 million in Q1 2026, up from €5 million prior year.

Competitors like DocMorris lag in customer acquisition costs, while Redcare's marketing efficiency yields a 25% revenue boost. Its scale in Germany provides a moat against new entrants amid strict EU pharmacy regulations.

Why Redcare Pharmacy matters for US investors

Listed on the Frankfurt Stock Exchange, Redcare Pharmacy offers US investors access to Europe's digital health boom without direct EU regulatory hurdles. With the US online pharmacy market valued at $100 billion and growing, parallels in consumer behavior make it a proxy for sector trends. Trading in EUR, it provides currency diversification amid USD strength.

Key dates and catalysts to watch

Upcoming Q2 results are scheduled for August 12, 2026, per the IR calendar. Potential catalysts include expansion into new EU markets and partnerships with health insurers, following a recent collaboration with a major German fund announced April 2026.

Regulatory changes on e-prescriptions across Europe could accelerate growth, with full implementation eyed by 2027.

Conclusion

Redcare Pharmacy demonstrates robust growth in the online pharmacy space, with Q1 results highlighting execution amid favorable sector tailwinds. While European regulations pose ongoing challenges, its market leadership and efficiency position it well. Investors tracking digital health will monitor upcoming quarters for sustained momentum.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.